Part of 赛诺菲安万特
Clinical Trials
425
59 active
Approvals
41
Total approvals
Agencies
5
Regulatory bodies
Founded
1990
Active, not recruiting
59
13.9%
Completed
340
80.0%
Recruiting
7
1.6%
Terminated
16
3.8%
Unknown
2
0.5%
Withdrawn
1
0.2%
- Sanofi Pasteur received a $10.6 million RISE PA grant to replace natural gas-fired dehydrators at its Swiftwater vaccine facility, reducing natural gas use by approximately 65%. - The project will cut 516 metric tons of CO2 equivalent in its first year and supports Sanofi's global ambition of net-zero greenhouse gas emissions by 2045. - The Swiftwater plant manufactures approximately 42% of all influenza vaccine doses that protect Americans annually, making it a critical national health security asset. - The modernization effort is expected to create approximately 40 new jobs, including union construction positions, while lowering energy costs for the facility.
- An interim analysis of the first-in-human Phase 1 trial of LASSARAB, an inactivated rabies-vectored Lassa fever vaccine, demonstrated 100% seroconversion against both Lassa virus and rabies virus by day 61 in healthy adults. - The vaccine was well tolerated across all dose groups, with no serious adverse events or grade ≥3 reactions; solicited symptoms were predominantly mild and self-limited. - All LASSARAB recipients achieved rabies-neutralizing antibody titers exceeding the WHO correlate of protection (≥0.5 IU/ml), matching responses seen with licensed rabies vaccines. - The study, published in Nature Medicine and conducted at the University of Maryland, supports advancing LASSARAB to larger trials in endemic settings, offering potential dual protection against two priority pathogens.
- Brazil's national drug regulator approved the world's first single-dose dengue vaccine, Butantan-DV, for use in people aged 12 to 59, marking a significant breakthrough in dengue prevention. - The vaccine demonstrated 74.7% overall efficacy and 91.6% efficacy against severe forms of dengue in late-stage trials involving 16,000 volunteers across Brazil. - The single-dose format will particularly benefit remote communities in hard-to-reach regions like the Amazon, eliminating the need for multiple clinic visits required by existing two-dose vaccines. - Brazil plans to incorporate the vaccine into its national immunization program by early 2026, with over 1 million doses ready for distribution following the country's worst dengue epidemic with 6.4 million cases and 5,972 deaths in 2024.
- Valneva announced plans to close its 3,178m² facility in Nantes, France, terminating 30 positions while consolidating French operations at its Lyon site. - The consolidation follows the FDA's suspension of Valneva's chikungunya vaccine Ixchiq due to safety concerns, significantly impacting the company's travellers' segment sales. - Despite the operational challenges, Valneva reported positive Phase II data for its Lyme disease vaccine candidate developed with Pfizer, showing robust immune response across all age groups. - The company will centralize all R&D activities at its Vienna site while maintaining its Euronext Paris listing and relocating its registered office back to Lyon.
- Clover Biopharmaceuticals has appointed Nicholas Jackson, Ph.D., as President of Global R&D and Alliances to accelerate development of its RSV+hMPV±PIV3 combination vaccine candidates. - Dr. Jackson brings over 27 years of vaccine development experience from leadership roles at GSK, Pfizer, and Sanofi Pasteur to advance Clover's respiratory vaccine portfolio. - The company's Trimer-Tag platform technology has demonstrated safety across 40,000+ doses and recently reported positive Phase I clinical data in older adults. - Jackson will focus on establishing global partnerships and alliances to maximize the public health impact of Clover's vaccine candidates and platform technology.
- Saint Louis University's Center for Vaccine Development will enroll up to 30 healthy adult volunteers in a Phase 1 clinical trial to evaluate the safety and immune response of an updated investigational West Nile virus vaccine. - The study addresses a critical unmet medical need, as no approved vaccine or treatment currently exists for West Nile virus, which has caused over 28,000 cases of neuroinvasive disease and 2,600 deaths in the U.S. since 1999. - Participants aged 18-49 will receive either the experimental vaccine or placebo across three doses over 13 months, with the trial being the only research site for this Phase 1 study. - The research builds on promising safety data from an earlier vaccine version and is funded by the National Institute of Allergy and Infectious Diseases as part of ongoing efforts to develop effective protection against this mosquito-borne pathogen.
- The US Department of Health and Human Services announced the termination of 22 mRNA vaccine projects valued at nearly $500 million, affecting contracts with major pharmaceutical companies and research institutions. - HHS Secretary Robert F. Kennedy Jr. cited data showing mRNA vaccines "fail to protect effectively against upper respiratory infections like COVID and flu" as justification for the policy shift. - The department is redirecting funding toward "safer, broader vaccine platforms" including whole-virus vaccines and novel platforms that aim to develop a "universal vaccine" mimicking natural immunity. - The decision impacts partnerships with Pfizer, Moderna, AstraZeneca, and other major players, while raising concerns about rapid pandemic response capabilities given mRNA technology's faster development timeline.
